Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Free Cash Flow (2016 - 2025)

Sunshine Biopharma's Free Cash Flow history spans 14 years, with the latest figure at -$1.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 53.96% year-over-year to -$1.6 million; the TTM value through Dec 2025 reached -$5.5 million, up 61.18%, while the annual FY2025 figure was -$5.5 million, 61.18% up from the prior year.
  • Free Cash Flow reached -$1.6 million in Q4 2025 per SBFM's latest filing, down from -$735840.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$297355.0 in Q1 2021 to a low of -$5.6 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$1.8 million, with a median of -$1.5 million recorded in 2025.
  • Peak YoY movement for Free Cash Flow: crashed 858.16% in 2021, then skyrocketed 74.18% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$312113.0 in 2021, then plummeted by 681.96% to -$2.4 million in 2022, then rose by 5.46% to -$2.3 million in 2023, then crashed by 52.03% to -$3.5 million in 2024, then soared by 53.96% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Free Cash Flow are -$1.6 million (Q4 2025), -$735840.0 (Q3 2025), and -$1.4 million (Q2 2025).